SINOVAC: Supply Vaccines to Eliminate Human Diseases

R&D and Innovation

SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.

Our Vaccines

SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac^®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive^®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive^®, Influenza Vaccine (Split Virion), Inactivated - Anflu^®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.

COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac^®

Validated by the World Health Organization's Emergency Use Listing ("EUL") Procedure on June 2, 2021

Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive^®

Launched in 2016.

Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive^®

Launched in 2002.

Influenza Vaccine Product Family

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent. Influenza Vaccine (Split Virion), Inactivated - Anflu^®. Pandemic Influenza Vaccine (Inactivated, Adjuvanted) - Panflu^®. H1N1 Influenza A Vaccine (Split Virion), Inactivated - Panflu.1^®.